GlobeNewswire

Leading Insurer Enlists Corvil Security Analytics to Reduce Cyber Risk

Dela

Firm cites superior visibility into user and host activity as well as integration into broader cybersecurity ecosystem among differentiators in selecting Corvil

NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Corvil today announced one of America's most highly rated financial institutions, with more than $80 billion in assets under management, has implemented Corvil Security Analytics to deliver real-time network traffic visibility, user activity analysis and network forensics to provide more comprehensive cyber threat detection and faster incident response.  

For the security team within this financial services firm, ensuring the security and compliance of sensitive data about millions of online customers was a strategic priority.  With more than 80 percent of breaches[1] stemming from inadvertent or malicious insiders, cyber attacks have the potential to wreak financial, reputational and compliance havoc.  According to reports[2], the number of cyber attacks against financial services companies has risen by more than 80 percent in the last year.  

In recognizing risks posed by its increasingly complex digital operations and looking for greater visibility within the network perimeter, the firm sought to fortify its security fabric. Following a competitive selection process, Corvil was enlisted to help mitigate risks associated with evasive threats. Among these threats are those that can often hide deep within normal network communications and seemingly appropriate user behavior, such as that of the firm's workforce and thousands of remote representatives.  Providing granular insights and integrated workflows, Corvil enabled faster and more complete investigations and threat hunting, resulting in more effective and efficient end-to-end security operations.  

Deployed across multiple data centers, Corvil's continuous packet capture, analysis, threat-matching, prioritization, and alerting extended the scope of threat detection across the corporate network.  The security team gained uniquely granular and contextualized insights into user and threat activity which drastically minimized the manual effort required for forensic investigation.

Dan Kennedy, Corvil VP and GM, Americas, said: "Incomplete or shallow information about suspicious activity can often be worse than none at all, owing to the tremendous overhead on security teams who must determine whether a breach has occurred and the impact thereof.  We have seen how empowering security analysts, of all levels, with greater insight can reduce attacker dwell times and improve the productivity of even high caliber security teams such as this customer."  

Corvil delivered intelligent integration with other best-of-breed security tools, extending the firm's protection fabric from the perimeter, across the network, and into endpoints, enabling the firm to:

  • Operationalize the use of threat intelligence for faster breach detection
  • Streamline and unify file extraction, threat analysis, and perimeter response with a leading next generation firewall provider
  • Simplify tracking of attack indicators and processes across the network and within hosts with Carbon Black Cb Response
  • Deliver further correlation of events and faster investigation through bidirectional workflows with a leading machine data analytics SIEM platform

Corvil's combination of unique insight and integration was a key differentiator during the competitive selection process. It enabled faster, more comprehensive response and maximized the value of their security ecosystem.   

"The advanced persistent threat landscape coupled with heightened regulatory oversight and stakeholder demands for utmost assurances from those charged with handling their sensitive data have caused cybersecurity technology budgets to surge [3] ," said  David Murray, Corvil Chief Marketing and Business Development Officer. "However a disparate and siloed set of cybersecurity technologies introduces greater levels of complexity to already overburdened security teams.  Time and time again, customers and analysts tell us that solutions designed to participate in a wider security ecosystem of data collection, analytics and policy enforcement are intrinsically more valuable. This latest win demonstrates that our strategy to design interoperable, best-of-breed solutions addresses this pressing market demand."

About Corvil
Corvil is the industry leader for deriving Security, Operational, and Business intelligence from network data. As companies adopt faster and smarter machine technology, it becomes critical to tap into richer and more granular machine data sources to safeguard the transparency, performance and security of critical infrastructure and business applications. The Corvil streaming analytics platform captures, decodes, and learns from network data on the fly, transforming it into machine-time intelligence for network, IT, security and business teams to operate efficiently and securely in this new machine world. Corvil uses an open architecture to integrate the power of its network data analytics with the overall IT ecosystem providing increased automation and greater operational and business value outcomes for its users. The Corvil solution is trusted by leading financial institutions to safeguard their businesses across the globe involving 354 trillion messages with a daily transaction value in excess of $1 trillion.

Learn more about Corvil: Corvil.com | Twitter | LinkedIn

Notes to the editor
[1] 81% of hacking-related breaches leveraged either stolen and/or weak passwords - 2017 Verizon DBIR. This means that 81% of attacks will come from hacker controlled machines inside the perimeter.
[2] https://www.professionaladviser.com/professional-adviser/news/3027071/fca-data-sees-financial-services-data-hacks-quadruple-in-2016-17
[3] According to the EY 20th Global Information Security Survey 2017-18, - 59% of respondents this year say their budgets increased over the last 12 months.                   

Contact information: 
Press Office at Corvil
+353 1 859 1040
pressoffice@corvil.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Corvil via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum